Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma

References

• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717–720.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Koshikawa T, Koike K, et al. Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Acta Pathol Jpn 1993;43:396–412.
   PubMedGoogle Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002;38:75–81.
   PubMed Web of Science ®Google Scholar
• Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 2003;44:241–249.
   PubMed Web of Science ®Google Scholar
• Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma):results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13:140–149.
   PubMed Web of Science ®Google Scholar
• Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma:the M. D. Anderson Cancer Center experience. Cancer 2005;103:2091–2098.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, Salles G, Coiffier B. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. Leukemia 2000;14:2159–2165.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvages regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997;11: 937–947.
   Web of Science ®Google Scholar
• Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma:experience in 44 patients. J Clin Oncol 2000;18:2603–2606.
   PubMed Web of Science ®Google Scholar
• Sallah S, Wehbie R, Lepera P, Sallah W, Bobzien W. The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. Br J Haematol 1999;104:163–165.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:51–58.
   PubMedGoogle Scholar
• Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma:a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004;101:1835–1842.
   PubMed Web of Science ®Google Scholar
• Chau I, Webb A, Cunningham D, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001;115:786–792.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Fabbri A, Puccini B, et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) +/- rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer 2010;116:4573–4579.
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Woynarowski JM, et al. Supraadditive effect of 2’, 2’-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117–123.
   PubMed Web of Science ®Google Scholar
• El GT, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363–1368.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Russo F, Capobianco G, et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol 2006;17(Suppl. 4):18–24.
   Google Scholar
• Jaffe ES, Harris NL, Stein H, et al., editors. Pathology & genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   Web of Science ®Google Scholar
• Evens AM, Gartenhaus RB. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004;5:289–303.
   PubMedGoogle Scholar
• Zain JM, O’Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 2010;92:33–44.
   PubMed Web of Science ®Google Scholar
• O’Connor OA. Novel agents in development for peripheral T-cell lymphoma. Semin Hematol 2010;47(Suppl. 1):S11–S14.
   PubMedGoogle Scholar
• Ng M, Waters J, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005;92:1352–1357.
   PubMed Web of Science ®Google Scholar